Xavier Paolettí

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial

Christophe Le Tourneau, Jean-Pierre Delord, Anthony Gonçalvès et al. · The Lancet Oncology · 2015 · 1.1K citations

Advanced Cancer, Drug Targeting, Oncology +12

Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

Esma Saâda-Bouzid, Cécile Defaucheux, Andy Karabajakian et al. · Annals of Oncology · 2017 · 596 citations

Oncology, Neoadjuvant Therapy, Anti-pd-1/pd-l1 Therapy +6

EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype

Sandra Rebouissou, Isabelle Bernard‐Pierrot, Aurélien de Reyniès et al. · Science Translational Medicine · 2014 · 380 citations

Muscle-invasive Bladder Carcinoma, Pathology, Cancer Biology +18

Emergency circulatory support in refractory cardiogenic shock patients in remote institutions: a pilot study (the cardiac-RESCUE program)

Sylvain Beurtheret, Pierre Mordant, Xavier Paolettí et al. · European Heart Journal · 2012 · 270 citations · Full text

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

Astrid Lièvre, Anthony Turpin, Isabelle Ray‐Coquard et al. · European Journal of Cancer · 2020 · 163 citations · Full text

Solid Cancer Patients, Cancer Epidemiology, Disease Risk Assessment +12